Posts by Sandra Ansanay-Alex
A VR training programme for medical students supported by Innosuisse
Viva VOsCE is a revolutionary project aiming at transforming medical education through harnessing the power of Virtual Reality (VR) technology. The project is being conducted in partnership with the Geneva University Hospitals (HUG) and the University of Bern, with ORamaVR S.A. as implementation partner. Objective Structured Clinical Examinations (OSCE) are critical for the practical…
Read MoreThree new projects financed in Geneva by the FIF
Plair, Endotelix and Dr Beat Walpoth received funding from the Fongit Innovation Fund (FIF). Plair SA: Growth loan of 300’000 CHF This spin-off from the University of Geneva specializes in the development, manufacturing and marketing of professional systems for preventive environmental monitoring, using a proprietary state-of-the-art technology that forms the basis of its smart…
Read MoreSenbiosys raises more than CHF 600,000 on kickstarter
Senbiosys developed a smart ring and an application to give users inputs about their health and wellness. The EPFL spin-off raised CHF 622 672 on a Kickstarter crowdfunding campaign with more than 3465 backers. The company initially requested CHF 100,000 in funding. A smart and elegant ring to monitor your health. Iris by Senbiosys…
Read MoreTech4Eva selected 16 projects for its 2023 programme
16 projects have been selected for the 2023 programme Tech4Eva is an EPFL Innovation Park and Groupe Mutuel initiative that aims at creating a long-term impact for FemTech startups and a global FemTech Community. The 2023 international cohort was selected from a total of 147 applications from 40 countries. Since the start of the…
Read MoreDebiopharm and Merck invest in artificial intelligence
Debiopharm Innovation Fund, the strategic investment arm of Swiss biopharmaceutical company Debiopharm, and M Ventures, the strategic, corporate venture capital arm of Merck, and Omnes Capital invested CHF 15.5 million in French startup Iktos By 2025, one in two drugs is expected to be discovered and developed using artificial intelligence. Iktos is a French…
Read MoreEFI-Lake Geneva Ventures and Yellowstone Holding AG invest CHF 3,5 million in Medyria
Medyria’s PyCath aims to be the only device on the market with pressure and blood flow velocity sensing for the invasive diagnosis of ischemic heart conditions. Medyria AG, is a Medtech company leader in blood flow velocity sensing. The start-up based in Winterthur recently launched the development of the PyCath a novel microcatheter for…
Read MoreSOPHiA GENETICS and Agilent Partner
SOPHiA GENETICS, a Lausanne-based cloud-native software company in the healthcare space and the leader in data-driven medicine, is partnering with Agilent, a US-based company providing measuring instruments for chemical analysis, life sciences, and diagnostics, to offer a comprehensive solution for cancer analysis. Through the partnership, the SOPHiA DDM™ Platform will be integrated with Agilent’s new Research…
Read MoreGeNeuro raises €25 million for its treatment against long COVID
GeNeuro develops timelimab, an antibody that showed promising results in treating inflammatory symptoms for long COVID patients GeNeuro, a Geneva-based biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID-19 (PASC, (PASC, post-COVID or long COVID), announced the signature…
Read MoreThree Jura start-ups awarded with the DayOne Tech accelerator prize
The Jura branch of the Swiss Innovation Park Basel Area is home to 28 companies and institutions, including ten in Medtech. Three of them just received an innovation prize. “We have set up an acceleration and coaching programme with people from the industry who will accompany each of the start-ups,” explains Florian Sanner,…
Read MoreDebiopharm expands its oncology pipeline
The Lausanne-based biotech company has obtained global rights from a Novo Nordisk molecule and plans to take the compound forward in overcoming resistant tumor types. Debiopharm announced having obtained the global rights for FT-3171, a small molecule USP1 inhibitor program targeting a novel DNA damage repair (DDR) pathway from Novo Nordisk. FT-3171…
Read More